Get started

Financials · BBOT

BridgeBio Oncology Therapeutics Inc. (BBOT) financials

For the twelve months ended Jun 30, 2026, BridgeBio Oncology Therapeutics Inc. reported $15.36M of revenue and -$182.11M of net income.

Revenue, TTM
$15.36M
Revenue growth, YoY
+90.1%
Net income, TTM
-$182.11M
Net margin
-1185.4%
Free cash flow, TTM
-$151.56M
Cash
$54.06M
P/S
12.00
Market cap
$184.4M
Annual revenue$11.34M
FY2024FY2025
Annual net income-$134.04M
FY2023FY2025
Annual free cash flow-$114.50M
FY2024FY2025

BBOT revenue and earnings growth

BBOT revenueQ2 2026$3.55M

Quarter YoY
+113.1%
QoQ
-10.0%
FY YoY
+77.9%

BBOT revenue was $3.55M in fiscal Q2 2026 (ended Jun 30, 2026), up 113.1% from a year earlier and down 10.0% from the prior quarter. For the full fiscal 2025 it was $11.34M, up 77.9% from fiscal 2024.

BBOT net incomeQ2 2026-$56.45M

BBOT net income was -$56.45M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$28.43M a year earlier. For the full fiscal 2025 it was -$134.04M, compared with -$74.28M in fiscal 2024.

BBOT EPSQ2 2026-$705.20

BBOT diluted EPS was -$705.20 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$4.30.

BBOT free cash flowQ2 2026-$44.41M

BBOT free cash flow was -$44.41M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$23.52M a year earlier. For the full fiscal 2025 it was -$114.50M, compared with -$55.08M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
Revenue$11.34M$6.38M-
Research and development$121.20M$73.11M-
Selling, general and admin$24.62M$7.76M$41.7K
Operating income-$145.82M-$80.86M-$41.7K
Income tax$0$0-
Net income-$134.04M-$74.28M-$41.7K
EPS, basic-$4.30-$5756.41-
EPS, diluted-$4.30-$5756.41-
Diluted shares31.1M12,903-

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
Cash and equivalents$373.69M$30.98M$250.0K
Short-term investments$51.77M$124.78M-
Current assets$432.40M$158.69M-
Total assets$448.38M$164.30M$332.9K
Current liabilities$35.04M$19.58M$396.5K
Total liabilities$37.28M$19.58M$396.5K
Shareholders' equity$411.10M-$178.64M-$115.64M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
Operating cash flow-$113.89M-$55.03M-
Capital expenditures$606.0K$49.0K-
Free cash flow-$114.50M-$55.08M-
Investing cash flow$73.33M-$120.53M-
Financing cash flow$383.40M$206.29M-
Stock-based compensation$5.87M$4.42M-

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
Revenue growth, YoY77.9%--
Operating margin-1285.5%-1268.0%-
Net margin-1181.7%-1164.7%-
Free cash flow margin-1009.4%-863.7%-
Return on equity-32.6%--
Return on assets-29.9%-45.2%-12.5%
Current ratio12.348.10-

Source: XBRL data BridgeBio Oncology Therapeutics Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

BBOT peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
BBOT$15.36M+90.1%-$182.11M-1185.4%$184.4M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

BBOT FAQ

7 questions
  • What is BBOT revenue?
    BridgeBio Oncology Therapeutics Inc. (BBOT) reported $15.36M of revenue for the twelve months ended Jun 30, 2026. That is up 90.1% from the year before. Revenue for fiscal 2025 was $11.34M.
  • Is BBOT profitable?
    No. BridgeBio Oncology Therapeutics Inc. reported a net loss of $182.11M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does BBOT have?
    BridgeBio Oncology Therapeutics Inc. reported $54.06M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is BBOT revenue growing?
    BridgeBio Oncology Therapeutics Inc.'s revenue changed +77.9% in fiscal 2025, to $11.34M.
  • What is BBOT free cash flow?
    BridgeBio Oncology Therapeutics Inc. generated -$151.56M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$151.28M less capital expenditures.
  • When did BBOT last report financial results?
    The latest statements here come from BridgeBio Oncology Therapeutics Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.
  • Where does this BBOT financial data come from?
    Quantisnow builds these statements from the structured XBRL data BridgeBio Oncology Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.